Plutavimab
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) [1][2].
Product Specifications
CAS Number
[2529854-88-2]
Product Name Alternative
COVI-AMG; STI-2020
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/plutavimab.html
Purity
98.619
Solubility
10 mM in DMSO|H2O
Smiles
[Plutavimab]
Molecular Weight
(143.981 kDa)
Precautions
H302, H315, H319, H335
References & Citations
[1]Williams, et al. Engineering of antibodies to coronavirus SARS-CoV-2 for diagnosis and treatment. World Intellectual Property Organization, WO2023070051 A1. 2023-04-27.|[2]Plutavimab. IMGT/mAb-DB.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15093627 1 Vial
Lentiviral human ZNF865 shRNA (UAS) - Lentiviral human ZNF865 shRNA (UAS, iRFP) (100)
Ask
View Details